Charles Allerson, Ph.D

Chief Technology Officer at Switch Therapeutics

Speaker

Charles "Chuck" Allerson is the Chief Technology Officer at Switch Therapeutics, and leads the development of the conditionally activated siRNA ("CASi") platform. Chuck has spent more than 20 years building nucleic acid chemical tools and applying them to the development of RNA-based therapeutics. Immediately prior to joining Switch, he served as Senior Vice President of Chemistry at DTx Pharma from 2019 until its acquisition by Novartis in 2023, and led efforts to develop the FALCON platform for the extrahepatic delivery of RNA therapeutics. He began his career as a chemist at Variagenics, and subsequently joined the Medicinal Chemistry team at Isis (now Ionis) Pharmaceuticals. Following his role at Ionis, he led early-stage and development stage chemistry at Regulus Therapeutics, and later spent time at Stoke Therapeutics as Vice President of Chemistry.